Keywords: fda, accepts, spectrum, sumatriptan, anda, pharmaceuticals, says
FDA accepts Spectrum's sumatriptan ANDA
Article | 17 January 2005
Spectrum Pharmaceuticals says that its Abbreviated New Drug Application for sumatriptan succinate injection 6mg/0.5mL, submitted last October, has been ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
